Psoriatic Arthritis - Pipeline Review, H1 2015
Summary
Global Markets Directs, Psoriatic Arthritis - Pipeline Review, H1 2015, provides an overview of the Psoriatic Arthritiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news and deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and RandD brief, licensing and collaboration details and other developmental activities
- The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective RandD development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Psoriatic Arthritis Overview 8
Therapeutics Development 9
Pipeline Products for Psoriatic Arthritis - Overview 9
Pipeline Products for Psoriatic Arthritis - Comparative Analysis 10
Psoriatic Arthritis - Therapeutics under Development by Companies 11
Psoriatic Arthritis - Therapeutics under Investigation by Universities/Institutes 15
Psoriatic Arthritis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Psoriatic Arthritis - Products under Development by Companies 20
Psoriatic Arthritis - Products under Investigation by Universities/Institutes 23
Psoriatic Arthritis - Companies Involved in Therapeutics Development 24
AbbVie Inc. 24
AbGenomics International, Inc. 25
Alder Biopharmaceuticals Inc. 26
Amgen Inc. 27
Avesthagen Limited 28
Biocon Limited 29
Bristol-Myers Squibb Company 30
Celgene Corporation 31
Celltrion, Inc. 32
Coherus BioSciences, Inc. 33
Covagen AG 34
Eli Lilly and Company 35
Epirus Biopharmaceuticals, Inc. 36
Genor BioPharma Co., Ltd. 37
Inbiopro Solutions Pvt. Ltd. 38
Innovent Biologics, Inc. 39
Johnson Johnson 40
Kineta, Inc. 41
Mabion SA 42
Momenta Pharmaceuticals, Inc. 43
Novartis AG 44
Oncobiologics, Inc. 45
Panacea Biotec Limited 46
Pfizer Inc. 47
Sandoz International GmbH 48
Swedish Orphan Biovitrum AB 49
Therapeutic Proteins International, LLC 50
UCB S.A. 51
Psoriatic Arthritis - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
abatacept (recombinant) - Drug Profile 61
AbGn-168H - Drug Profile 64
ABT-122 - Drug Profile 66
adalimumab biosimilar - Drug Profile 68
adalimumab biosimilar - Drug Profile 69
adalimumab biosimilar - Drug Profile 70
adalimumab biosimilar - Drug Profile 71
adalimumab biosimilar - Drug Profile 72
adalimumab biosimilar - Drug Profile 73
adalimumab biosimilar - Drug Profile 74
adalimumab biosimilar - Drug Profile 75
adalimumab biosimilar - Drug Profile 76
anakinra (recombinant) - Drug Profile 77
apremilast - Drug Profile 78
bimekizumab - Drug Profile 81
brodalumab - Drug Profile 82
clazakizumab - Drug Profile 84
COVA-322 - Drug Profile 86
dalazatide - Drug Profile 87
etanercept biosimilar - Drug Profile 89
etanercept biosimilar - Drug Profile 90
etanercept biosimilar - Drug Profile 91
etanercept biosimilar - Drug Profile 92
etanercept biosimilar - Drug Profile 93
etanercept biosimilar - Drug Profile 94
etanercept biosimilar - Drug Profile 95
etanercept biosimilar - Drug Profile 96
golimumab - Drug Profile 97
golimumab biosimilar - Drug Profile 100
guselkumab - Drug Profile 101
IBI-303 - Drug Profile 104
IBPM-004AM - Drug Profile 105
IBPM-005IX - Drug Profile 106
infliximab biosimilar - Drug Profile 107
infliximab biosimilar - Drug Profile 109
infliximab biosimilar - Drug Profile 110
infliximab biosimilar - Drug Profile 111
infliximab biosimilar - Drug Profile 112
INV-17 - Drug Profile 113
itolizumab - Drug Profile 114
ixekizumab - Drug Profile 116
Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - Drug Profile 117
secukinumab - Drug Profile 118
tofacitinib - Drug Profile 122
Psoriatic Arthritis - Recent Pipeline Updates 126
Psoriatic Arthritis - Dormant Projects 176
Psoriatic Arthritis - Discontinued Products 177
Psoriatic Arthritis - Product Development Milestones 178
Featured News Press Releases 178
Appendix 186
Methodology 186
Coverage 186
Secondary Research 186
Primary Research 186
Expert Panel Validation 186
Contact Us 186
Disclaimer 187
List Of Tables
Number of Products under Development for Psoriatic Arthritis, H1 2015 12
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Comparative Analysis by Unknown Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Psoriatic Arthritis - Pipeline by AbbVie Inc., H1 2015 27
Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H1 2015 28
Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H1 2015 29
Psoriatic Arthritis - Pipeline by Amgen Inc., H1 2015 30
Psoriatic Arthritis - Pipeline by Avesthagen Limited, H1 2015 31
Psoriatic Arthritis - Pipeline by Biocon Limited, H1 2015 32
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2015 33
Psoriatic Arthritis - Pipeline by Celgene Corporation, H1 2015 34
Psoriatic Arthritis - Pipeline by Celltrion, Inc., H1 2015 35
Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2015 36
Psoriatic Arthritis - Pipeline by Covagen AG, H1 2015 37
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2015 38
Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 39
Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2015 40
Psoriatic Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 41
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H1 2015 42
Psoriatic Arthritis - Pipeline by Johnson Johnson, H1 2015 43
Psoriatic Arthritis - Pipeline by Kineta, Inc., H1 2015 44
Psoriatic Arthritis - Pipeline by Mabion SA, H1 2015 45
Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 46
Psoriatic Arthritis - Pipeline by Novartis AG, H1 2015 47
Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H1 2015 48
Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H1 2015 49
Psoriatic Arthritis - Pipeline by Pfizer Inc., H1 2015 50
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2015 51
Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2015 52
Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H1 2015 53
Psoriatic Arthritis - Pipeline by UCB S.A., H1 2015 54
Assessment by Monotherapy Products, H1 2015 55
Number of Products by Stage and Target, H1 2015 57
Number of Products by Stage and Mechanism of Action, H1 2015 59
Number of Products by Stage and Route of Administration, H1 2015 61
Number of Products by Stage and Molecule Type, H1 2015 63
Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H1 2015 129
Psoriatic Arthritis - Dormant Projects, H1 2015 179
Psoriatic Arthritis - Discontinued Products, H1 2015 180
List Of Figures
Number of Products under Development for Psoriatic Arthritis, H1 2015 12
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Products, H1 2015 21
Assessment by Monotherapy Products, H1 2015 55
Number of Products by Top 10 Targets, H1 2015 56
Number of Products by Stage and Top 10 Targets, H1 2015 56
Number of Products by Top 10 Mechanism of Actions, H1 2015 58
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 58
Number of Products by Top 10 Routes of Administration, H1 2015 60
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 61
Number of Products by Top 10 Molecule Types, H1 2015 62
Number of Products by Stage and Top 10 Molecule Types, H1 2015 63
